Kestrel Fund tied to PROCEPT BioRobotics (PRCT) director buys 426K shares
Filing Impact
Filing Sentiment
Form Type
4
Rhea-AI Filing Summary
PROCEPT BioRobotics Corp director-linked entity Kestrel Fund, L.P. reported open-market purchases of 426,262 shares of common stock over several days. The buys occurred on March 5, 6 and 9, 2026 at weighted average prices generally between the low $20s and mid $20s per share, as detailed in price ranges in the footnotes. The filing also shows 35,152 shares held directly and 14,363 shares held indirectly by The 2:22 DNA Trust as of March 5, 2026. Antal Rohit Desai, a director and managing partner of CPMG, Inc., may be deemed to share voting and investment power over Kestrel Fund holdings but disclaims beneficial ownership except to the extent of any pecuniary interest.
Positive
- None.
Negative
- None.
Insider Trade Summary
Net Buyer: 426,262 shares ($10,482,943)
Net Buy
9 txns
Insider
Desai Antal Rohit
Role
Director
Bought
426,262 shs ($10.48M)
| Type | Security | Shares | Price | Value |
|---|---|---|---|---|
| Purchase | Common Stock | 43,581 | $24.0816 | $1.05M |
| Purchase | Common Stock | 53,818 | $24.9052 | $1.34M |
| Purchase | Common Stock | 1,300 | $25.4173 | $33K |
| Purchase | Common Stock | 106,554 | $23.3282 | $2.49M |
| Purchase | Common Stock | 53,763 | $24.1019 | $1.30M |
| Purchase | Common Stock | 142,498 | $25.4391 | $3.63M |
| Purchase | Common Stock | 24,748 | $26.4073 | $654K |
| holding | Common Stock | -- | -- | -- |
| holding | Common Stock | -- | -- | -- |
Holdings After Transaction:
Common Stock — 371,144 shares (Indirect, Kestrel Fund, L.P.);
Common Stock — 35,152 shares (Direct)
Footnotes (1)
- The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $25.0645 to $26.0213, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the ranges set forth in this footnote. CPMG, Inc. is the general partner and investment manager of Kestrel Fund, L.P. Antal Desai, a member of the Issuer's board of directors and a shareholder and managing partner of CPMG, Inc., may be deemed to share voting and investment power with respect to the shares beneficially owned by Kestrel Fund, L.P. Mr. Desai disclaims beneficial ownership of the shares beneficially owned by Kestrel Fund, L.P. except to the extent of any pecuniary interest therein. The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $26.10 to $26.98, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the ranges set forth in this footnote. The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $22.785 to $23.75, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the ranges set forth in this footnote. The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $23.79 to $24.50, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the ranges set forth in this footnote. The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $23.40 to $24.39, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the ranges set forth in this footnote. The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $24.40 to $25.39, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the ranges set forth in this footnote. The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $25.40 to $25.44, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the ranges set forth in this footnote.
FAQ
What insider transactions did PROCEPT BioRobotics (PRCT) report on this Form 4?
The Form 4 reports that Kestrel Fund, L.P., an entity associated with director Antal Rohit Desai, purchased a total of 426,262 shares of PROCEPT BioRobotics common stock in open-market transactions across March 5, 6 and 9, 2026, increasing its reported indirect holdings.
What additional PROCEPT BioRobotics (PRCT) holdings are reported besides Kestrel Fund, L.P.?
The filing lists 35,152 shares of PROCEPT BioRobotics common stock held directly, and 14,363 shares held indirectly by The 2:22 DNA Trust as of March 5, 2026. These entries are reported as holdings, not new open-market purchase transactions.